FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136807097> ?p ?o ?g. }

• W3136807097 endingPage "1329" @default.
• W3136807097 startingPage "1329" @default.
• W3136807097 abstract "Objectives: IgG4-related disease (IgG4-RD) is a chronic fibro-inflammatory disorder affecting virtually any organ. Type 1 autoimmune (type 1 AIP) is its pancreatic manifestation. To date, steroids are considered the first-line pancreatitis treatment. The CD20-binding antibody rituximab (RTX) appears a promising steroid-sparing therapy, although long-term data are lacking. We aimed to bridge this gap with a cohort of IgG4-RD patients treated with RTX and to assess the potential value of the Responder Index (RI) as a discriminatory score for disease activity. Methods: We retrospectively evaluated 46 patients from a tertiary referral centre who were diagnosed with IgG4-RD and/or type 1 AIP according to the International Consensus Diagnostic Criteria or Unifying-AIP criteria between June 2006 and August 2019. Results: Patients resembled previous cohorts in terms of characteristics, diagnosis, and therapeutic response. Thirteen of the 46 patients with IgG4-RD/type 1 AIP were treated with RTX pulse therapy due to relapse, adverse reactions to steroids, or high-risk constellations predicting a severe course of disease with multi-organ involvement. Median follow-up after diagnosis was 52 months for all subjects, and 71 months in IgG4-RD patients treated with RTX. While patients in the RTX group showed no significant response to an initial steroid pulse, clinical activity as measured by the RI significantly decreased in the short-term after RTX induction. Within 16 months, 61% of patients relapsed in the RTX group but responded well to re-induction. Clinical and laboratory parameters improved equally in response to RTX. Conclusion: RTX therapy in patients with IgG4-RD is an effective and safe treatment to induce treatment response and possible long-term remission. Repeated RTX administration after 6–9 months may be of value in reducing the risk of relapse. The RI appears to be a reasonable index to assess disease activity and to identify patients with IgG4-related disease who may benefit from B-cell-depleting therapy." @default.
• W3136807097 created "2021-03-29" @default.
• W3136807097 creator A5014475022 @default.
• W3136807097 creator A5021152840 @default.
• W3136807097 creator A5034891779 @default.
• W3136807097 creator A5038707544 @default.
• W3136807097 creator A5049271441 @default.
• W3136807097 creator A5055082801 @default.
• W3136807097 creator A5059480753 @default.
• W3136807097 creator A5088450042 @default.
• W3136807097 date "2021-03-23" @default.
• W3136807097 modified "2023-10-14" @default.
• W3136807097 title "A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab" @default.
• W3136807097 cites W1550734019 @default.
• W3136807097 cites W1993726826 @default.
• W3136807097 cites W1998363181 @default.
• W3136807097 cites W2031477993 @default.
• W3136807097 cites W2035861698 @default.
• W3136807097 cites W2039130348 @default.
• W3136807097 cites W2042567949 @default.
• W3136807097 cites W2042657838 @default.
• W3136807097 cites W2075300336 @default.
• W3136807097 cites W2081330562 @default.
• W3136807097 cites W2082783569 @default.
• W3136807097 cites W2100918713 @default.
• W3136807097 cites W2109475734 @default.
• W3136807097 cites W2110662561 @default.
• W3136807097 cites W2126983369 @default.
• W3136807097 cites W2139500303 @default.
• W3136807097 cites W2143651115 @default.
• W3136807097 cites W2168664357 @default.
• W3136807097 cites W2293761297 @default.
• W3136807097 cites W2507782211 @default.
• W3136807097 cites W2518504487 @default.
• W3136807097 cites W2565747216 @default.
• W3136807097 cites W2595817625 @default.
• W3136807097 cites W2610128427 @default.
• W3136807097 cites W2725088452 @default.
• W3136807097 cites W2755478460 @default.
• W3136807097 cites W2790090724 @default.
• W3136807097 cites W2792613800 @default.
• W3136807097 cites W2793356363 @default.
• W3136807097 cites W2794151501 @default.
• W3136807097 cites W2806274364 @default.
• W3136807097 cites W2898787731 @default.
• W3136807097 cites W2910643896 @default.
• W3136807097 cites W2953716147 @default.
• W3136807097 cites W2993448153 @default.
• W3136807097 cites W2993526648 @default.
• W3136807097 cites W2997643687 @default.
• W3136807097 cites W3033192349 @default.
• W3136807097 cites W3035831639 @default.
• W3136807097 cites W3047226664 @default.
• W3136807097 cites W3087106109 @default.
• W3136807097 doi "https://doi.org/10.3390/jcm10061329" @default.
• W3136807097 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8004657" @default.
• W3136807097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33807051" @default.
• W3136807097 hasPublicationYear "2021" @default.
• W3136807097 type Work @default.
• W3136807097 sameAs 3136807097 @default.
• W3136807097 citedByCount "14" @default.
• W3136807097 countsByYear W31368070972021 @default.
• W3136807097 countsByYear W31368070972022 @default.
• W3136807097 countsByYear W31368070972023 @default.
• W3136807097 crossrefType "journal-article" @default.
• W3136807097 hasAuthorship W3136807097A5014475022 @default.
• W3136807097 hasAuthorship W3136807097A5021152840 @default.
• W3136807097 hasAuthorship W3136807097A5034891779 @default.
• W3136807097 hasAuthorship W3136807097A5038707544 @default.
• W3136807097 hasAuthorship W3136807097A5049271441 @default.
• W3136807097 hasAuthorship W3136807097A5055082801 @default.
• W3136807097 hasAuthorship W3136807097A5059480753 @default.
• W3136807097 hasAuthorship W3136807097A5088450042 @default.
• W3136807097 hasBestOaLocation W31368070971 @default.
• W3136807097 hasConcept C126322002 @default.
• W3136807097 hasConcept C167135981 @default.
• W3136807097 hasConcept C18031839 @default.
• W3136807097 hasConcept C2775967933 @default.
• W3136807097 hasConcept C2778192524 @default.
• W3136807097 hasConcept C2779134260 @default.
• W3136807097 hasConcept C2779338263 @default.
• W3136807097 hasConcept C2780224187 @default.
• W3136807097 hasConcept C2780653079 @default.
• W3136807097 hasConcept C71924100 @default.
• W3136807097 hasConcept C72563966 @default.
• W3136807097 hasConcept C90924648 @default.
• W3136807097 hasConceptScore W3136807097C126322002 @default.
• W3136807097 hasConceptScore W3136807097C167135981 @default.
• W3136807097 hasConceptScore W3136807097C18031839 @default.
• W3136807097 hasConceptScore W3136807097C2775967933 @default.
• W3136807097 hasConceptScore W3136807097C2778192524 @default.
• W3136807097 hasConceptScore W3136807097C2779134260 @default.
• W3136807097 hasConceptScore W3136807097C2779338263 @default.
• W3136807097 hasConceptScore W3136807097C2780224187 @default.
• W3136807097 hasConceptScore W3136807097C2780653079 @default.
• W3136807097 hasConceptScore W3136807097C71924100 @default.
• W3136807097 hasConceptScore W3136807097C72563966 @default.
• W3136807097 hasConceptScore W3136807097C90924648 @default.

• next